A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids

Autor: Edward Kerwin, Steven Pascoe, Zelie Bailes, Robert Nathan, David Bernstein, Ronald Dahl, Robyn von Maltzahn, Kevin Robbins, Andrew Fowler, Laurie Lee

Publikováno v: Respiratory Research, Vol 21, Iss 1, Pp 1-15 (2020)

Abstract Background Patients with asthma uncontrolled on inhaled corticosteroids may benefit from umeclidinium (UMEC), a long-acting muscarinic antagonist. Methods This Phase IIb, double-blind study included patients with reversible, uncontrolled/par

Externí odkaz: https://doaj.org/article/80784703907a451aa2b0d49c0e29f44f

Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)

Autor: James F. Donohue, Edward Kerwin, Sanjay Sethi, Brett Haumann, Srikanth Pendyala, Lorna Dean, Chris N. Barnes, Edmund J. Moran, Glenn Crater

Publikováno v: Respiratory Research, Vol 20, Iss 1, Pp 1-10 (2019)

Abstract Background Revefenacin is a long-acting muscarinic antagonist that was recently approved for the nebulized treatment of chronic obstructive pulmonary disease (COPD). Although shorter duration studies have documented the efficacy of revefenac

Externí odkaz: https://doaj.org/article/198bfe3495a340e7a38a0033b3384475

A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease

Autor: Krishna K. Pudi, Chris N. Barnes, Edmund J. Moran, Brett Haumann, Edward Kerwin

Publikováno v: Respiratory Research, Vol 18, Iss 1, Pp 1-11 (2017)

Abstract Background Revefenacin is a once-daily long-acting muscarinic antagonist (LAMA) in clinical development for the treatment of patients with chronic obstructive pulmonary disease (COPD). In a dose-ranging study, nebulized once-daily revefenaci

Externí odkaz: https://doaj.org/article/bc165cac9e6d4e7c99cd0b0f6dfd0275

Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults : phase 1/2 randomized clinical trial

Autor: Isabel Leroux-Roels, Matthew G Davis, Katie Steenackers, Brandon Essink, Corinne Vandermeulen, Charles Fogarty, Charles P Andrews, Edward Kerwin, Marie-Pierre David, Laurence Fissette, Carline Vanden Abeele, Delphine Collete, Magali de Heusch, Bruno Salaun, Nathalie De Schrevel, Juliane Koch, Céline Verheust, Nancy Dezutter, Frank Struyf, Narcisa Mesaros, Jelena Tica, Veronica Hulstrøm

Publikováno v: JOURNAL OF INFECTIOUS DISEASES

Background The aim of this study was to investigate safety and immunogenicity of vaccine formulations against respiratory syncytial virus (RSV) containing the stabilized prefusion conformation of RSV fusion protein (RSVPreF3). Methods This phase 1/2,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::538a4339e7015f8decaa4c0e105e5b1d
https://biblio.ugent.be/publication/01GWJE5RBJ48X5RXKXPD83JEVH

Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial

Autor: Joseph K Han, Claus Bachert, Wytske Fokkens, Martin Desrosiers, Martin Wagenmann, Stella E Lee, Steven G Smith, Neil Martin, Bhabita Mayer, Steven W Yancey, Ana R Sousa, Robert Chan, Claire Hopkins, Cecilia Ahlström Emanuelsson, Ledit Ardusso, Michael Armstrong, Philip Bardin, Sara Barnes, Miguel Bergna, Christian Betz, Achim Beule, James Blotter, Valeriu Bronescu, Matthew Brown, Sean Carrie, Adam Chaker, Hyung-Ju Cho, Marie-Noëlle Corriveau, Timothy Courville, Mandy Cuevas, Cecelia Damask, Adam DeConde, Jaime Del Carpio, María De Salvo, Hun-Jong Dhong, Stephen Durham, Anton Edin, Dale Ehmer Jr, Pedro Elías, Adil Fatakia, Christine Franzese, Simon Gane, Gabriel García, Andrew Gillman, Moritz Groeger, Richard Harvey, Johan Hellgren, Thomas Higgins, Jonathan Hobson, Mattias Jangard, Arif Janjua, Naveed Kara, Sergey Karpischenko, Edward Kerwin, Fatimat Khanova, Shaun Kilty, Chang-Hoon Kim, Seontae Kim, Ludger Klimek, Craig LaForce, Samuel Leong, Bradley Marple, Anders Mårtensson, Jorge Maspero, Neil Massey, Jonathan Matz, Chad McDuffie, Corina Mella, Steven Miller, Ekaterina Mirzabekyan, Jonathan Moss, Nayla Mumneh, Robert Nathan, Adriana Neagos, Heidi Olze, Andrey Ovchinnikov, Randall Ow, Dmitriy Polyakov, Doinel Radeanu, Chae-Seo Rhee, Ramón Rojas, Jeffrey Rosenbloom, Sergei Ryazantsev, Chady Sader, Pablo Saez Scherbovsky, Guy Scadding, Rodney Schlosser, Heena Shah-Patel, Ronald Shealy, Ayesha Siddiqi, Stacey Silvers, Narinder Singh, Doron Sommer, Weily Soong, Leigh Sowerby, Peter Spafford, Catalin Stefan, Richard Sterling, Valeriy Svistushkin, Neetu Talreja, Galina Tarasova, Martha Tarpay, Alberto Tolcachier, Karin Toll Toll, Carolina van Schaik, Luke Webb, H James Wedner, Luis Wehbe, Soo Whan Kim, Barbara Wollenberg, Simon Wright, Vladimir Yakusevich, Anahí Yañez, Yury Yarin, David Yen, Hyo Yeol Kim

Publikováno v: lancet. Respiratory medicine, 9(10), 1141-1153. Elsevier Limited

Background: Chronic rhinosinusitis with nasal polyps affects approximately 2–4% of the general population, and long-term use of systemic corticosteroids is associated with adverse effects. The aim of this study was to assess the efficacy and safety

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bc6772624170fd7c789ee5290b4827b
https://doi.org/10.1016/s2213-2600(21)00097-7